Altimmune Draws $10 Million Under Hercules Capital Loan Agreement
Bitget2026/10/29 11:20- Altimmune drew $10 million in Tranche Three on October 27, 2026, under a $125 million loan agreement with Hercules Capital and other lenders.
- Meeting clinical and financial milestones extended the interest-only period and amortization date to June 1, 2028.
- The minimum cash covenant now requires qualified cash equal to at least 60% of outstanding Term Loan Advances principal.
- A 1% tranche facility charge was deducted from funding; the end-of-term charge remains 6.25% of amounts funded.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
